Niche MRI vendor Advanced MammographySystems will debut its long-awaited MR mammography scanner atthe RSNA show. The company, which is a subsidiary of fast MRIdeveloper Advanced NMR Systems, will also hold a special briefingon Sunday, Nov. 27, to unveil
Niche MRI vendor Advanced MammographySystems will debut its long-awaited MR mammography scanner atthe RSNA show. The company, which is a subsidiary of fast MRIdeveloper Advanced NMR Systems, will also hold a special briefingon Sunday, Nov. 27, to unveil the unit.
AMS has yet not released the name of the system, but the scannerfeatures a 0.5-tesla superconducting magnet similar in appearanceto a standard MRI scanner, according to Robert Kwolyk, vice presidentof sales and marketing for the Wilmington, MA, company. Thereare significant differences, however: Patients will enter themagnet bore feet first and in a prone position, with the breastshanging through holes in the patient table. The scanner's specialradio-frequency coils are embedded within the table, Kwolyk said.
The scanner will feature sequences optimized for breast imaging,according to Kwolyk. The company is reluctant to discuss whetherthe scanner will be used for screening, lesion differentiationor both, preferring instead to leave the development of clinicalapplications up to physicians. Use of the scanner for imagingleaks in silicone breast implants is one application whose utilityis already evident, however.
The scanner has been designed to support an integrated breastbiopsy capability that may be developed in the future, accordingto Kwolyk. It may also be possible to integrate breast therapywith the system.
Advanced Mammography Systems has designed the system for cost-effectivescanning, Kwolyk said. The price of the system will probably beunder $500,000 and the scanner can complete an examination in15 minutes. The system sites in less than 300 square feet. Thecompany is in the process of filing a 510(k) application for theproduct.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.